Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020;17:541–54.

Article  PubMed  Google Scholar 

Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43:2026–36.

Article  PubMed  Google Scholar 

Australian Institute of Health and Welfare. Cancer in Australia 2019. Cancer series no.119. Cat. no. CAN 123. Canberra: AIHW; 2019.

Kolling S, Ventre F, Geuna E, Milan M, Pisacane A, Boccaccio C, et al. “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”? Front Oncol. 2019;9:1546.

Article  PubMed  Google Scholar 

Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272–80.

Article  CAS  PubMed  Google Scholar 

Urban D, Rao A, Bressel M, Lawrence YR, Mileshkin L. Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer. 2013;109:1318–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, et al. Familial risk in patients with carcinoma of unknown primary. JAMA Oncol. 2016;2:340–6.

Article  PubMed  Google Scholar 

Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v133–8.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Occult Primary (Version 1.2022). 2019. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf.

National Institute for Health and Care Excellence (NICE). Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. 2010. https://www.nice.org.uk/guidance/cg104.

Walker MS, Weinstein L, Luo R, Marino I. Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary. J Comp Eff Res. 2018;7:523–33.

Article  PubMed  Google Scholar 

Hyphantis T, Papadimitriou I, Petrakis D, Fountzilas G, Repana D, Assimakopoulos K, et al. Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncology. 2013;22:2009–15.

Article  PubMed  Google Scholar 

Wagland R, Bracher M, Drosdowsky A, Richardson A, Symons J, Mileshkin L, et al. Differences in experiences of care between patients diagnosed with metastatic cancer of known and unknown primaries: mixed-method findings from the 2013 cancer patient experience survey in England. BMJ Open. 2017;7:e017881.

Article  PubMed  PubMed Central  Google Scholar 

Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit Rev Oncol Hematol. 2020;147:102882.

Article  PubMed  Google Scholar 

Kramer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:228–46.

Article  CAS  PubMed  Google Scholar 

Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428–35.

Article  PubMed  Google Scholar 

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013;231:413–23.

Article  CAS  PubMed  Google Scholar 

Ross JS, Sokol ES, Moch H, Mileshkin L, Baciarello G, Losa F, et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist. 2021;26:e394–e402.

Article  CAS  PubMed  Google Scholar 

Mileshkin LR, Sivakumaran T, Etemadmoghadam D, Tothill R, Fellowes A, Fox SB, et al. Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: experience of the first two years. J Clin Oncol. 2019;37:3072.

Article  Google Scholar 

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

Article  CAS  PubMed  Google Scholar 

Cancer Council Australia. Optimal care pathway for people with cancer of unknown primary. 2020. https://www.cancer.org.au/assets/pdf/cancer-of-unknown-primary-january-2020.

Tan SYS, O’Neill S, Goldstein D, Ward RL, Daniels B, Vajdic CM. Predictors of care for patients with cancer of unknown primary site in three Australian hospitals. Asia Pac J Clin Oncol. 2018;14:e512–e20.

Article  PubMed  Google Scholar 

Stares M, Purshouse K, Knowles G, Haigh R, Irvine J, Gatenby A, et al. Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis. Br J Cancer. 2021;125:1503–10.

Article  PubMed  PubMed Central  Google Scholar 

Posner A, Prall OW, Sivakumaran T, Etemadamoghadam D, Thio N, Pattison A, et al. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. J Pathol. 2023;259:81–92.

Article  CAS  PubMed  Google Scholar 

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491–505.

Article  CAS  PubMed  Google Scholar 

Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol. 2019;37:570–9.

Article  CAS  PubMed  Google Scholar 

Fizazi K, Maillard A, Penel N, Baciarello G, Allouache D, Daugaard G, et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol. 2019;30:v851–v934.

Article  Google Scholar 

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217–23.

Article  CAS  PubMed  Google Scholar 

Moran S, Martinez-Cardus A, Sayols S, Musulen E, Balana C, Estival-Gonzalez A, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:1386–95.

Article  PubMed  Google Scholar 

Fusco MJ, Knepper TC, Balliu J, Del Cueto A, Laborde JM, Hooda SM, et al. Evaluation of targeted next-generation sequencing for the management of patients diagnosed with a cancer of unknown primary. Oncologist. 2022;27:e9–e17.

Article  PubMed  PubMed Central  Google Scholar 

Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross JS, et al. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist. 2021;26:e769–e79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mileshkin L, Bochtler T, Gatta G, Kurzrock R, Beringer A, Muller-Ohldach M, et al. Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice. Cancers (Basel). 2022;14:2905.

Article  PubMed  Google Scholar 

Vajdic CM, Er CC, Schaffer A, Dobbins T, Wyld L, Meagher NS, et al. An audit of cancer of unknown primary notifications: a cautionary tale for population health research using cancer registry data. Cancer Epidemiol. 2014;38:460–4.

Article  PubMed  Google Scholar